This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Bruce M. Romanic, MD
Wilmington, Del

JAMA. 1986;255(7):904.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

I found Dr Jeresaty's¹ recent update on mitral valve prolapse in the Aug 9 issue of JAMA very useful. I would like to comment, however, on the use of antiplatelet therapy in these patients.

As was mentioned, mitral valve prolapse probably plays a role in cerebral ischemia, at least in patients younger than 45 years of age.²I would also like to point to a study concerning platelet coagulant hyperactivity in patients with mitral valve prolapse.³ In this study, 100% of patients with mitral valve prolapse and thromboembolic complications showed platelet coagulant hyperactivity, as did 58% of patients with mitral valve prolapse but no history of thromboembolic or visual manifestations. This compared with only 6% of a control group without mitral valve prolapse showing platelet coagulant hyperactivity.

Given this information, antiplatelet prophylaxis appears reasonable, especially in those patients who express concern, verbally or nonverbally, about . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?